Alloreactive host peptide–Human Leukocyte Antigen complex (pHLA complex)

Alloreactive host peptide–Human Leukocyte Antigen (HLA) complexes are molecular assemblies consisting of a host-derived peptide fragment bound within the groove of a host HLA molecule (Janeway et al., Immunobiology, 2001). These complexes are expressed on the surface of host cells and serve as the primary ligands for donor T-cell receptors (TCRs) following allogeneic hematopoietic stem cell transplantation or solid organ transplantation (Shlomchik, Nature Reviews Immunology, 2007). The recognition of these 'non-self' complexes by donor T cells, a process termed allorecognition, triggers robust T-cell activation, proliferation, and differentiation (Ferrara et al., The Lancet, 2009). This immune response is the fundamental driver of Graft-versus-Host Disease (GvHD), where donor immune cells attack host tissues such as the skin, liver, and gastrointestinal tract (Zeiser & Blazar, New England Journal of Medicine, 2017). In solid organ transplantation, similar recognition leads to acute or chronic allograft rejection. Therapeutic strategies targeting this interaction include the use of calcineurin inhibitors like Tacrolimus to block downstream signaling, costimulation blockers like Abatacept to prevent full T-cell activation, and experimental TCR-like antibodies designed to target specific alloreactive pHLA complexes (Kourelis et al., Blood, 2016). Managing these targets is a delicate balance between preventing GvHD and maintaining the beneficial graft-versus-leukemia (GvL) effect, where donor cells eliminate residual cancer cells (Appelbaum, Nature, 2001).

Other names

Alloreactive pHLAHost peptide-MHC complexAllo-HLA-peptide complexMinor histocompatibility antigen-HLA complexAlloreactive host peptide–HLA complexes

Inhibition of T-cell receptor (TCR) recognition of the pHLA complex, suppression of downstream T-cell signaling, or blockade of costimulatory pathways required for activation.